{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:56:03Z","timestamp":1793836563393,"version":"4.6.1"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Hypofractionated radiotherapy for prostate cancer has recently gained attention, with growing evidence supporting the clinical use of hypofractionation. This retrospective study aimed to compare the outcomes of hypofractionated radiotherapy with conventional fractionation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 2012 and 2021, patients with low\u2010 or intermediate\u2010risk prostate cancer treated at our institution were included. Patients were divided into two groups: the conventional group (78.0\u2009Gy in 39 fractions over 8\u2009weeks) and the hypofractionated group (51.6\u2009Gy in 12 fractions over 2.5\u2009weeks). Survival outcomes and toxicities were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 96 patients were included: 54 in the conventional group and 42 in the hypofractionated group. The median follow\u2010up time was 110.5\u2009months (IQR: 78.3\u2013125.0) in the conventional group and 73.5\u2009months (IQR: 57.8\u201383.5) in the hypofractionated group. Only one patient in the conventional group experienced biochemical recurrence. There were no significant differences in acute grade \u2265\u20092 urinary or bowel toxicity between the two groups. Grade \u2265\u20092 late urinary toxicity was more frequent in the hypofractionated group (16.7% vs. 7.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.16), while grade \u2265\u20092 late bowel toxicity was more frequent in the conventional group (16.7% vs. 4.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hypofractionated radiotherapy demonstrated comparable oncological outcomes and an acceptable toxicity profile to those of conventionally fractionated radiotherapy in patients with low\u2010 to intermediate\u2010risk prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70391","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:27:35Z","timestamp":1772972855000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low\u2010 and Intermediate\u2010Risk Localized Prostate Cancer"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-9128","authenticated-orcid":false,"given":"Kota","family":"Iida","sequence":"first","affiliation":[{"name":"Department of Urology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Urology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Itami","sequence":"additional","affiliation":[{"name":"Department of Urology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Osaka City General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Itagaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinari","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Urology Tane General Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-2464","authenticated-orcid":false,"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University  Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"National Cancer Center Japan Cancer Information Service \u201cTrends in Cancer Incidence Rates by Site [in Japanese] \u201d(2025) https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/20_prostate.html."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30102\u20104"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30070\u20105"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.0448"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7397"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31131\u20106"},{"key":"e_1_2_11_8_1","volume-title":"Clinical Practice Guidelines for Prostate Cancer 2023 [in Japanese]","author":"Japanese Urological Association","year":"2023"},{"key":"e_1_2_11_9_1","first-page":"38","volume-title":"General Rules for Clinical and Pathological Studies on Prostate Cancer, 5th Ed. [in Japanese]","author":"The Japanese Urological Association","year":"2022"},{"key":"e_1_2_11_10_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 4.2025","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"e_1_2_11_12_1","volume-title":"EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer: 2025 (\u201cProstate Cancer \u2013 Limited Update March 2025\u201d) [Internet]","author":"Cornford P.","year":"2025"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.08.002"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.06.202"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.02.000"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.06.008"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360\u20103016(00)00577\u20100"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.11.024"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00117\u2010X"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360\u20103016(01)022664\u20105"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.08.009"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20190829"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:26Z","timestamp":1787669966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/iju.70391"],"URL":"https:\/\/doi.org\/10.1111\/iju.70391","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70391"}}